Valuation of PAR, page-5

Nice numbers. To me it really does not matter what calculation is used. IF Zilosul gets FDA approval then the price today looks absolutely ridiculous.

It’s the risk inherent in Biotechs and that most investors stay away from them that creates the opportunity. Most would just see us as a binary event drug company but wouldn’t take to time to see why we may be a little different. Very much still under the radar.

The risk reward here is heavily skewed towards the brave investors that buy or are holding today.

However, serious returns will be made by those that buy today or are holding and then still holding the core of their shares in 10 years time.

Still risk here though so DYOR and don’t over commit.